How Often Do Sentinel Lymph Node Biopsy Results Affect Adjuvant Therapy Decisions Among Postmenopausal Women with Early-Stage HR+/HER2− Breast Cancer in the Post-RxPONDER Era?
Pilewskie M, Sevilimedu V, Eroglu I, Le T, Wang R, Morrow M, Braunstein LZ. How Often Do Sentinel Lymph Node Biopsy Results Affect Adjuvant Therapy Decisions Among Postmenopausal Women with Early-Stage HR+/HER2− Breast Cancer in the Post-RxPONDER Era? Annals Of Surgical Oncology 2022, 29: 6267-6273. PMID: 35849294, PMCID: PMC10286823, DOI: 10.1245/s10434-022-12193-w.Peer-Reviewed Original ResearchConceptsSentinel lymph node biopsyAxillary lymph node dissectionAdjuvant therapy decisionsPostmenopausal womenNodal irradiationRecurrence scoreBreast cancerPositive nodesTherapy decisionsMedian age 62 yearsOncotype DX recurrence scorePT2-3 tumorsLymph node dissectionLymph node biopsyLow recurrence scoreAge 62 yearsDX recurrence scoreCT1-2N0MethodsPostmenopausal womenNodal pathologyPN0 stagePositive SLNRxPONDER trialAxillary stagingNode dissectionAccuracy of the Breast Cancer Surveillance Consortium Model Among Women with LCIS
Eroglu I, Sevilimedu V, Park A, King TA, Pilewskie ML. Accuracy of the Breast Cancer Surveillance Consortium Model Among Women with LCIS. Breast Cancer Research And Treatment 2022, 194: 257-264. PMID: 35595928, PMCID: PMC10229518, DOI: 10.1007/s10549-021-06499-8.Peer-Reviewed Original ResearchConceptsInvasive breast cancer riskBreast cancer riskBCSC modelBreast cancerCancer riskBreast densityPrior breast cancerBenign breast diseaseInvasive breast cancerKaplan-Meier methodTime-dependent receiverChemoprevention useCumulative incidenceInvasive cancerLobular carcinomaBreast diseaseIncidence rateFamily historyRisk scoreFair discriminationLCISCancerWomenRisk predictionConsortium model